Equities research analysts predict that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will announce $70,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Bellicum Pharmaceuticals’ earnings. The lowest sales estimate is $30,000.00 and the highest is $100,000.00. Bellicum Pharmaceuticals reported sales of $130,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 46.2%. The company is expected to announce its next quarterly earnings report on Monday, May 14th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full year sales of $70,000.00 for the current financial year, with estimates ranging from $120,000.00 to $400,000.00. For the next financial year, analysts forecast that the business will post sales of $3.20 million per share, with estimates ranging from $500,000.00 to $5.90 million. Zacks’ sales averages are an average based on a survey of research firms that cover Bellicum Pharmaceuticals.
Several brokerages have recently weighed in on BLCM. Cantor Fitzgerald set a $10.00 target price on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. Citigroup lifted their target price on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the company a “hold” rating in a report on Friday, February 16th. ValuEngine downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. SunTrust Banks lowered their target price on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating on the stock in a report on Wednesday, January 31st. Finally, Wells Fargo & Co downgraded shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price on the stock. in a report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $16.88.
Shares of Bellicum Pharmaceuticals (BLCM) traded up $0.14 during trading hours on Friday, hitting $8.22. 1,020,668 shares of the stock traded hands, compared to its average volume of 944,991. The stock has a market capitalization of $272.03, a P/E ratio of -2.74 and a beta of 0.44. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals has a 1-year low of $5.02 and a 1-year high of $15.55.
In related news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total value of $2,248,978.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 1,141,822 shares of company stock valued at $9,475,583 in the last quarter. Company insiders own 18.77% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors lifted its stake in shares of Bellicum Pharmaceuticals by 30.4% in the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,620 shares during the period. The Manufacturers Life Insurance Company raised its position in Bellicum Pharmaceuticals by 26.6% during the second quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 4,684 shares during the last quarter. New York State Common Retirement Fund raised its position in Bellicum Pharmaceuticals by 30.8% during the second quarter. New York State Common Retirement Fund now owns 28,000 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 6,599 shares during the last quarter. California State Teachers Retirement System raised its position in Bellicum Pharmaceuticals by 16.7% during the second quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock worth $562,000 after acquiring an additional 6,900 shares during the last quarter. Finally, D.A. Davidson & CO. raised its position in Bellicum Pharmaceuticals by 17.4% during the third quarter. D.A. Davidson & CO. now owns 47,650 shares of the biopharmaceutical company’s stock worth $550,000 after acquiring an additional 7,050 shares during the last quarter. Hedge funds and other institutional investors own 55.14% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.